<DOC>
	<DOCNO>NCT01225510</DOCNO>
	<brief_summary>Angiopoietin-2 ( Ang-2 ) protein body destabilize blood vessel important stimulating tumor blood vessel . There evidence suggest Ang-2 may important growth progression Glioblastoma multiforme ( GBM ) . PF- 04856884 ( CVX-060 ) compound bind Ang-2 prevents activity . The hypothesis PF-04856884 safe effective patient recurrent Glioblastoma multiforme ( GBM ) .</brief_summary>
	<brief_title>A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma</brief_title>
	<detailed_description>Notification study cancel result update overall status change `` yet recruit '' `` withdrawn . ''</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>Tumor eligibility : Primary Cohort : Measurable disease ; Exploratory Cohort : Measurable disease define nonmeasurable/evaluable disease ( eg , progress nonenhancing lesion ) . Histologically cytologically confirm recurrent GBM 1st 2nd relapse : Primary Cohort : Recurrence follow radiation therapy temozolomide , less equal 2 prior chemotherapeutic regimen ; Exploratory cohort : Prior radiation therapy , temozolomide , bevacizumab , Recurrence disease within 24 week last bevacizumab dose . Stable dose corticosteroid great equal 5 day prior baseline Magnetic Resonance Imaging ( MRI ) Adequate organ function Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy great equal 12 week . Patients previously receive trial drug contain core platform antibody ( eg , CVX045 , PF04856884 ( CVX060 ) , CVX096 , PF05057459 ( CVX241 ) , etc. ) . History pathologic fistula , gastrointestinal perforation , intraabdominal abscess within 6 month therapy . Evidence bleed diathesis coagulopathy . Major surgical procedure ( eg , craniotomy ) , open biopsy , significant traumatic injury within 28 day prior therapy anticipation need major surgical procedure course trial . Minor surgical procedure , fine needle aspiration core biopsy within 7 day prior therapy . Serious nonhealing wound , ulcer , bone fracture . Active gastrointestinal bleeding , evidence either hematemesis , hematochezia , melena prior 6 month . Hemoptysis &gt; Â½ teaspoon per day within 1 week enrollment . National Cancer InstituteCommon Terminology Criteria Adverse Events [ NCI CTCAE ] Grade 3 hemorrhage cause &lt; 4 week prior enrollment . Participation investigational drug study within 28 day prior study therapy . Evidence preexist uncontrolled hypertension Clinically significant cardiovascular disease within 12 month prior start trial treatment Prolongation QT interval correct [ QTc ] interval &gt; 450 msec men &gt; 470 msec woman . History allergic anaphylactic reaction therapeutic diagnostic monoclonal antibody IgGfusion protein . Exclusion Criteria Specific Primary Cohort Prior therapy bevacizumab antiVascular Endothelial Growth Factor [ VEGF ] agent treatment GBM . Exclusion Criteria Specific Exploratory Cohort Patients discontinue prior bevacizumab antiVEGF agent due toxicity . Patients fail 2 prior antiVEGF therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>recurrent glioblastoma multiforme ( GBM )</keyword>
	<keyword>CVX-060</keyword>
	<keyword>PF-04856884</keyword>
	<keyword>phase 2</keyword>
	<keyword>open-label</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>anti-angiogenic</keyword>
</DOC>